AXIM
AXIM BIOTECHNOLOGIES, INC.
Key Financials
Net Income
$-8059682
↓ 29.1%
Gross Profit
$187103
↑ 3867.4%
Revenue
$39518
↑ 345.3%
Operating Income
$-2750839
↑ 40.9%
EPS (Diluted)
$-0.04
↓ 200.0%
Total Assets
$4.1M
↓ 2.1%
Total Liabilities
$11.8M
↑ 30.3%
Cash & Equivalents
$47282.00
↓ 89.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 15-12G | 12/6/2024 | View on SEC |
| NT 10-Q | 11/13/2024 | View on SEC |
| 4 | 10/15/2024 | View on SEC |
| 8-K | 10/15/2024 | View on SEC |
| 10-Q | 8/19/2024 | View on SEC |
| NT 10-Q | 8/13/2024 | View on SEC |
| 10-Q/A | 5/22/2024 | View on SEC |
| 10-Q | 5/20/2024 | View on SEC |
| NT 10-Q | 5/15/2024 | View on SEC |
| 10-K | 4/16/2024 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AXIM |
| Company Name | AXIM BIOTECHNOLOGIES, INC. |
| CIK | 1514946 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | (212) 751-0001 |